Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

Support program for early postpartum mothers on outpatient medications for opioid use disorder

Official title: Adaptation and Implementation of an Evidence-Based Parenting Intervention for Postpartum Women Receiving Medications for Opioid Use Disorder

Run by University of Arkansas · NCT07071766 · Data updated 2026-11-12

This program will test whether Proud of Baby and Me helps pregnant women and those up to 12 months postpartum who are on outpatient medications for opioid use disorder stay in treatment and manage parenting and mental health stress.

More Parenting trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment10 (estimated)
SponsorUniversity of Arkansas
Academic / other
Locations1 site (Little Rock, Arkansas)
StatusRecruiting
StartedSeptember 1, 2026
Main results expectedJune 30, 2027
Study endsJune 30, 2027
Registry record updatedSeptember 9, 2026
Trial IDNCT07071766 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 or older who speak English, can give informed consent, are receiving outpatient medications for opioid use disorder, and are between 28 weeks gestation and up to 12 months postpartum.

Probably not a fit

People who are not yet 28 weeks gestation or more than 12 months postpartum at enrollment, not receiving outpatient MOUD, unable to consent, or who do not speak English are unlikely to benefit from this program.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional pilot implemented at an outpatient MOUD clinic will deliver the Proud of Baby and Me program to people between 28 weeks gestation and 12 months postpartum who are receiving methadone or buprenorphine. The program provides recovery-oriented support targeting common postpartum stressors such as return to opioid use, depression, parenting challenges, neonatal abstinence concerns, and stigma. Outcomes will focus on continued engagement in MOUD and reductions in parenting- and mental-health-related barriers to recovery. The trial is conducted at the University of Arkansas for Medical Sciences in Little Rock.

Why it matters

Potential benefit: If successful, the program could help postpartum women on MOUD stay in treatment longer, reduce overdose risk, and improve parenting and mental health outcomes.

How similar studies have gone: Previous work documents high postpartum MOUD discontinuation and some supportive programs have improved retention, but targeted postpartum interventions of this type remain limited and partly untested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 18 years or older
* Understand and speak English
* Able to give informed consent
* Receiving medications for opioid use disorder in the outpatient clinical setting
* Between 28 weeks gestation and up to 12 months postpartum

Exclusion Criteria:

* Unwilling to consent
* Before 28 weeks gestation and beyond 12 months postpartum at enrollment

Where it's running

  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas, United States
    Recruiting

Study contacts

  • Principal investigator: Mollee K Steely Smith, PhD — University of Arkansas
  • Study coordinator: Mollee K Steely Smith, PhD
  • Email: mksteelysmith@uams.edu
  • Phone: 501-526-8174

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.